centerforbiosimilars7h
The Top 5 Biosimilar Articles for the Week of September 16
Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...
centerforbiosimilars2d
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...
centerforbiosimilars3d
FDA Approves Pavblu for Retinal Conditions
Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...
centerforbiosimilars4d
Expanding Biosimilar Adoption: Insights and Strategies with Dr Sophia Humphreys
Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of ...
centerforbiosimilars5d
STADA Credits Biosimilar Expansion for Profitable First Half of 2024
German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 ...
centerforbiosimilars6d
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority ...